GenEmbryomics Limited (XGEN)
GenEmbryomics was planning to go public, but the IPO was withdrawn on Apr 23, 2025.
IPO Price
$4.75
Shares Offered
1,095,000
Deal Size
$5.20M
GenEmbryomics Statistics
Total Valuation
GenEmbryomics has a market cap or net worth of $43.25 million. The enterprise value is $43.92 million.
| Market Cap | 43.25M |
| Enterprise Value | 43.92M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
GenEmbryomics has 9.11 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 9.11M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | 0.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.14 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -1,396.10% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.98M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.81M |
| Pretax Income | -1.98M |
| Net Income | -1.98M |
| EBITDA | -1.81M |
| EBIT | -1.81M |
| Earnings Per Share (EPS) | -$0.22 |
Balance Sheet
The company has $41,578 in cash and $710,877 in debt, giving a net cash position of -$669,299 or -$0.07 per share.
| Cash & Cash Equivalents | 41,578 |
| Total Debt | 710,877 |
| Net Cash | -669,299 |
| Net Cash Per Share | -$0.07 |
| Equity (Book Value) | -961,952 |
| Book Value Per Share | -0.11 |
| Working Capital | -962,155 |
Cash Flow
| Operating Cash Flow | -1.17M |
| Capital Expenditures | n/a |
| Free Cash Flow | -1.17M |
| FCF Per Share | -$0.13 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GenEmbryomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -4.59% |
| FCF Yield | -2.70% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |